Department of Neurosurgery, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, 101, Laarbeeklaan, 1090, Brussel, Belgium.
Acta Neurol Belg. 2013 Mar;113(1):49-54. doi: 10.1007/s13760-012-0128-8. Epub 2012 Sep 14.
The purpose of this study is to evaluate long-term results in acromegaly patients who received surgery as first-line treatment. Repeated surgery, radiation therapy and medical treatment were considered in patients showing no postoperative remission or who suffered a relapse. Thirty-five patients suffering from acromegaly were operated on between 1993 and 2009. The patients with persistent hypersecretion received a new surgery when postoperative imaging showed localized residual lesion. The other cases with persistent hypersecretion were treated medically using dopamine agonists, somatostatin analogs or pegvisomant according to the efficiency obtained. Radiotherapy was considered when medical treatment failed to normalize hormonal hypersecretion. The overall remission rate with surgery alone was 57 % (20/35):84 % (16/19) with non-invasive adenomas and 25 % (4/16) with invasive adenomas. Fifteen patients showing no remission after surgery received additional medical and/or radiation therapy resulting in hormonal control in ten of them. Recurrences after initial postoperative remission were observed in six patients who were controlled with subsequent therapy. Using a multimodal treatment approach, the disease was brought under control in 86 % (30/35) of acromegaly patients. Surgery alone produced satisfactory initial results in non-invasive adenomas, but additional treatments were required for most of the invasive lesions.
本研究旨在评估接受手术作为一线治疗的肢端肥大症患者的长期结果。对于术后无缓解或复发的患者,考虑重复手术、放射治疗和药物治疗。1993 年至 2009 年间对 35 例肢端肥大症患者进行了手术。对于术后影像学显示局部残留病变的持续性高分泌患者,给予新手术。对于其他持续性高分泌的病例,根据获得的疗效,使用多巴胺激动剂、生长抑素类似物或培维索孟进行药物治疗。当药物治疗不能使激素分泌过多正常化时,考虑放射治疗。单独手术的总体缓解率为 57%(20/35):非侵袭性腺瘤为 84%(16/19),侵袭性腺瘤为 25%(4/16)。术后无缓解的 15 例患者接受了额外的药物和/或放射治疗,其中 10 例激素得到控制。6 例初始术后缓解后复发的患者接受了后续治疗,病情得到控制。采用多模式治疗方法,86%(30/35)的肢端肥大症患者病情得到控制。单独手术对非侵袭性腺瘤有满意的初始效果,但大多数侵袭性病变需要额外的治疗。